Pharma-Bio Serv, Inc. (PBSV) Stock Price & Analysis
Pharma-Bio Serv, Inc. (PBSV) — price $0.48 (0.00%), as of the Nov 19, 2026 trading session; market cap $11.0M.
Educational signal · not a buy or sell recommendation · How to read this
Pharma-Bio Serv, Inc. · PBSV
Pharma-Bio Serv, Inc. is a specialized consulting firm providing regulatory compliance and technology transfer services to pharmaceutical, biotech, medical device, and food industries. It operates across Puerto Rico, the US, Europe, and Brazil, offering expertise in system validation, engineering, and project management.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.48 | |
| Change on the day | 0.00% | |
| Market capitalisation | $11.0M | — |
| Price / earnings (trailing) | 212.28 | |
| Shares traded on the day | 500 |
Price & events
Other perspectives
Council score for Pharma-Bio Serv (PBSV): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 3, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 3, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Pharma-Bio Serv (PBSV), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Pharma-Bio Serv, Inc. (PBSV) is the company analyzed here. It employs 55 people. In Q3 FY2026 it reported revenue of $2M and net income of -$14M. The market values it at $11.0M.
What do the latest results show for Pharma-Bio Serv (PBSV)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $2M. Against analyst estimates the company has EPS beat 0 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $2M | -$14M | -$0.0010 (diluted) |
| Q2 FY2026 | $3M | $232,986 | $0.01 (diluted) |
| Q1 FY2026 | $2M | $32,860 | $0.0014 (diluted) |
| Q4 FY2025 | $2M | -$102 | -$0.37 (diluted) |
What are the financial strengths and risks for Pharma-Bio Serv (PBSV)?
Short answer · as of
The distress and quality screens read Altman Z 2.19 · Piotroski F 3. Trailing ratios: ROE -0.3% · ROA -0.1% · current ratio 11.30 · earnings yield -121.9%.
Data-derived red flags
- Negative return on equity (-0.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PBSV in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PBSV in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Pharma-Bio Serv (PBSV)
These answers are editorial: 1 of these 8 answers is drawn from the PBSV research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is PBSV a good stock to buy?
Stock Expert AI does not rate PBSV buy, sell or hold. Pharma-Bio Serv, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PBSV stock price today?
The last price recorded for Pharma-Bio Serv, Inc. (PBSV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What specialized services does Pharma-Bio Serv, Inc. provide to the healthcare sector?
Pharma-Bio Serv, Inc. functions as a specialized consulting firm offering critical services primarily focused on regulatory compliance and the transfer of technology within highly regulated industries.
What are the key factors to evaluate for PBSV?
Evaluate PBSV on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Analysts target $1.55 (+223%). Increasing Regulatory Scrutiny: Global regulatory bodies, such as the FDA, EMA, and ANVISA, are continuously tightening compliance standards across the pharmaceutical, biotechnology, and medical device industries. Not financial advice.
How frequently does PBSV data refresh on this page?
PBSV's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PBSV's recent stock price performance?
Pharma-Bio Serv, Inc. (PBSV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in regulatory compliance and technology transfer for highly regulated industries. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PBSV overvalued or undervalued right now?
The trailing P/E of Pharma-Bio Serv, Inc. (PBSV) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PBSV before investing?
Before investing in Pharma-Bio Serv, Inc. (PBSV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 9 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com